Emerging Strategies for Bioactive Agent-Loaded Xenogeneic Bone Scaffolds in Regenerative Medicine: A Comprehensive Review
Zhang J., Qin W., Yue W., Zhang W., Zhao Y., Xu G.
Narrative Review, published in Drug Des Devel Ther (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Drug Des Devel Ther (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41368588
- PMCID
- PMC12683258
- DOI
- 10.2147/dddt.s560876
- Citations
- 2
Abstract (original English)
The escalating global burden of an aging population and the rising incidence of secondary traumatic injuries have precipitated a mounting worldwide demand for bone grafts. However, autologous bone transplantation-the prevailing clinical "gold standard"-remains insufficient to meet this growing clinical need. Notably, rapid advancements in bone tissue engineering (BTE) have yielded diverse bone graft substitutes designed to recapitulate the three essential characteristics of bone tissue: osteoconductivity, osteoinductivity, and osteogenic potential. Within this domain, core scaffolds functioning as carriers for bioactive agents represent a highly promising strategy for treating bone defects. This review focuses on the design and fabrication of optimal xenogeneic bone scaffolds. It systematically examines commonly loaded bioactive components, including bone morphogenetic proteins (BMPs), platelet-rich plasma (PRP), natural products, active ingredients derived from traditional Chinese medicine ingredients (TCMs), and exosomes. The advantages and limitations inherent to these agents are critically analyzed. Furthermore, the review addresses current challenges and explores future research directions in bone scaffold engineering. By advancing multimodal strategies for modulating the delivery of bioactive agents, we aim to provide more effective therapeutic solutions for patients with
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.